<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347800">
  <stage>Registered</stage>
  <submitdate>16/03/2012</submitdate>
  <approvaldate>1/05/2012</approvaldate>
  <actrnumber>ACTRN12612000478819</actrnumber>
  <trial_identification>
    <studytitle>The effect of night milk versus day milk in insomnia</studytitle>
    <scientifictitle>Randomised double blind cross over study of night milk versus day milk on insomnia symptoms in adults aged 25-60 years</scientifictitle>
    <utrn />
    <trialacronym>MOOS study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Insomnia</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Night milk: 30minutes prior to bed take product orally daily for 3 weeks.  Night milk is from cows milked at night and contains milk protein (600mg/100g).  Dose: 250ml (25g of total milk powder).
There will be a one week wash-out period before starting arm 2 of the study.</interventions>
    <comparator>Day milk: 30minutes prior to bed take product orally daily for 3 weeks. Day milk is a product made from cows milked during the day and contains milk protein (600mg/100g).  Dose: 250ml (25g of total milk powder).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sleep onset latency, using EEG from overnight study and estimate over one week from actigraphy.</outcome>
      <timepoint>Week 3 of 3 week trial.SOL from EEG will be assess on one occasion only - day 21 and actigraphy from each night of week three.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subjective sleep quality.  PROMIS Pittsburgh sleep quality index , Functional Outcomes of Sleep Questionnaire</outcome>
      <timepoint>Week 3 of 3 week trial.  This will be assessed across every night of week 3.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Wake after sleep onset.  This will be assessed using EEG during an overnight sleep study on night 21.</outcome>
      <timepoint>Week 3 of 3 week trial.  It will be measured on one occasion - day 21.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PROMIS sleep disturbance questionnaire</outcome>
      <timepoint>week 3 of 3 week trial.  This will be assess on each night of week 3.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PROMIS sleep related impairment questionnaire</outcome>
      <timepoint>week 3 of 3 week trial.  This will be assessed on each night of week 3.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Sleep onset latency &gt;30min
Adult 25-60 years
PSQI score &gt;= 7</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Other sleep disorders such as OSA, PLMS, narcolepsy
Taking prescription drugs that a) aid sleep b) promote weight loss c) alter mood d) prevent sleep
Allergies to dairy products
High consumer of caffeine
Shift worker</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Once a subject has met the enrolment criteria they will be allocated a treatment sequence using a closed urn randomisation of A/B or B/A-see below.</concealment>
    <sequence>Prospective urn randomisation using a (2,1) sdchedule was used.  A container with two coloured paper clips was prepared.  One clip was blindly withdrawn and its corresponding treated noted on a folded piece of paper in an opaque nevelope which wa then sealed.  This was repeated until 20 envelopes are created.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2012</anticipatedstartdate>
    <actualstartdate>28/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>17/04/2013</actualenddate>
    <samplesize>19</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>PO Box 56
DUNEDIN 9054</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Synlait Milk Ltd</fundingname>
      <fundingaddress>1028 Heslerton Road, RD 13, Rakaia 7783
Canterbury</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is designed to investigate whether night milk (from cows milked at night plus a milk protein) has an effect on insomnia symptoms compared to day milk (milk from cows milked during the day).  Queries regarding the trial can be submitted to: Dr Angela Campbell, Department of Medicine University of Wellington p: + 6449208819 f: + 6449208861 e: wellsleep@paradise.net.nz</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multi Region Ethics committee</ethicname>
      <ethicaddress>C/- MOH
PO BOX 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>14/02/2012</ethicapprovaldate>
      <hrec>MEC/11/12/099</hrec>
      <ethicsubmitdate>21/11/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Angela Campbell</name>
      <address>Dept Medicine
University of Otago Wellington
PO Box 7343 Wellington 6242</address>
      <phone>+64 4 9208819</phone>
      <fax />
      <email>wellsleep@paradise.net.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Angela Campbell</name>
      <address>Dept Medicine
University of Otago Wellington
PO Box 7343 Wellington 6242</address>
      <phone>+64 4 9208819</phone>
      <fax />
      <email>wellsleep@paradise.net.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Angela campbell</name>
      <address>Dept Medicine
University of Otago Wellington
PO Box 7343 Wellington 6242</address>
      <phone>+64 4 9208819</phone>
      <fax />
      <email>wellsleep@paradise.net.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Angela Campbell</name>
      <address>Dept Medicine
University of Otago Wellington
PO Box 7343
23a Mein St
Newtown
Wellington 6035
New Zealand</address>
      <phone>+64 4 9208819</phone>
      <fax />
      <email>wellsleep@paradise.net.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>